Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference
06 janv. 2022 16h05 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have...
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 déc. 2021 16h05 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...
Gain Therapeutics Progresses Krabbe Disease Program and Provides Scientific Update
07 déc. 2021 08h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...